CureVac N.V. Overview
Pro stress-test →CureVac N.V. is a biopharmaceutical company focused on developing medicines based on messenger RNA (mRNA), applying its technology to oncology precision immunotherapies, prophylactic vaccines, and treatments that enable the human body to produce its own therapeutic proteins. On January 6, 2026, CureVac completed a reorganization following BioNTech SE's acquisition, with BioNTech becoming the sole owner of all CureVac business operations.
Strategic Profile
Pro stress-test →Founded in 2000, CureVac has more than two decades of experience developing and manufacturing mRNA, with headquarters in Tübingen, Germany, and operations in the Netherlands, Belgium, Switzerland, and the United States. The company achieved regulatory progress in early 2025 with FDA clearance for CVHNLC, its lung cancer candidate, and completed glioblastoma study CVGBM enrollment in Q1 2025.
Competitive Landscape
Pro stress-test →CureVac competes in the mRNA-based therapeutics space, facing competition from established biotechs developing cancer immunotherapies and precision oncology solutions. Key industry relationships include partnerships with GSK, BioNTech (now parent company), and collaborations with CRISPR Therapeutics and MD Anderson Cancer Center for oncology programs. The competitive landscape includes large pharma companies and specialized immunotherapy developers pursuing similar mRNA approaches to cancer treatment.
Industry Context
CureVac N.V. operates in mRNA-based oncology immunotherapies.
Key facts
Founded: 2000 · Headquarters: Tübingen, Germany · Employees: N/A · Revenue: €56.3M (YTD 2025) · Market cap: N/A